Top in ID: COVID-19 vaccine, antimicrobial-resistant infections

AstraZeneca has halted its phase 3 trial of a COVID-19 vaccine following an adverse reaction in a participant from the United Kingdom. It was the top story in infectious disease last week.

Another top story was about new guidance from the Infectious Diseases Society of America for the clinical treatment of three common drug-resistant pathogens.

Read these and more top stories in infectious disease below:

AstraZeneca halts COVID-19 vaccine trial following adverse reaction in UK participant

AstraZeneca’s phase 3 trial of a COVID-19 vaccine candidate has been put on hold because of a “suspected serious adverse reaction” in a participant from the United Kingdom, according to a report by STAT. Read more.

IDSA issues new guidance for antimicrobial-resistant infections

The Infectious Diseases Society of America has issued new guidance for the treatment of three common drug-resistant pathogens: extended-spectrum beta-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales and difficult-to-treat resistance Pseudomonas aeruginosa. Read more.

Influenza season could create ‘perfect storm’ for COVID-19 outbreaks

Coinfection of COVID-19 and influenza and the effects of the influenza season on the pandemic have been a growing topic of concern for many infectious disease specialists. Read more.

Prolonged fever identifies patients at risk for adverse COVID-19 outcomes

Prolonged fever lasting more than 7 days after illness onset can help physicians identify patients at high risk for adverse outcomes from COVID-19, according to a study. Read more.

‘Just one missed case’: Study underscores importance of full travel screening

An analysis of records from more than 156,000 patient encounters in the Massachusetts General Hospital ED revealed that most included a general travel screening, but records rarely included documentation of where the patient traveled. Read more.